In the article entitled SCOMP Is Superior to Degenerated Oligonucleotide Primed-Polymerase Chain Reaction for Global Amplification of Minute Amounts of DNA from Microdissected Archival Tissue Samples (Volume 161, pages 43–51 of the July 2002 issue), the primers listed in Table 2 for D5S500 were incorrect. The correct primer sequences are: 5′-GTATCGGTGAAATGCAACTA-3′ and 5′-CTTTTTACATTTTTGGTACCTTG-3′.
In the article entitled Abnormal Uterine Bleeding during Progestin-Only Contraception May Result from Free Radical-Induced Alterations in Angiopoietin Expression (Volume 161, pages 979–986 of the September 2002 issue), the grant information was incorrect. The correct grant information is National Institutes of Health grant RO1 HD33937–06.
In the article entitled Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies (Volume 163, pages 1021–1031 of the September 2003 issue), Figures 3, 4, and 5 should have appeared in color. The corrected article, including color figures, appears at http://ajp.amjpathol.org/cgi/content/full/163/3/1021.
In the article entitled Expression of Calcium-Binding Proteins MRP8 and MRP14 in Inflammatory Muscle Diseases (Volume 163, pages 947–956 of the September 2003 issue), the authors’ affiliations should have read as follows:
Stephan Seeliger,*† Thomas Vogl,* Ingo Hubert Engels,* J. Michael Schröder,‡ Clemens Sorg,* Cord Sunderkötter,*§ and Johannes Roth*†
From the Institute of Experimental Dermatology,* the Department of Pediatrics,† University of Münster, Münster; the Department of Neuropathology,‡ University Hospital, RWTH-Aachen, Aachen; and the Department of Dermatology and Allergy,§ University of Ulm, Ulm, Germany
In the article entitled Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression (Volume 163, pages 1013–1020 of the September 2003 issue), the second author’s name was incorrectly spelled. The correct spelling for this author’s name is Alexander Hergovich.
In the article entitled Up-Regulation of Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer’s Disease (Volume 163, pages 591–607 of the August 2003 issue), several errors appeared in the print edition. The seventh author’s name should have read Inge Grundke-Iqbal. Throughout the article, references to “R134”, “134 days” and “R134 days” should have read “R134 days”. Other minor errors have also been noted. Please refer to http://ajp.amjpathol.org/cgi/content/full/163/2/591/DC1 for the corrected pdf of this article.
In the article entitled Detection of Oncofetal H19 RNA in Rheumatoid Arthritis Synovial Tissue (Volume 163, pages 901–911 of the September 2003 issue), the last sentence of the third paragraph on page 903 should have read as follows: “Alternatively, the housekeeping gene β-actin (downstream primer: GTGCGACGAAGACGAGACC; upstream primer: CAGAGCCG AGACACCACG; resulting fragment length, 230 bp) was used as an internal standard (conditions: initial denaturation at 93°C for 3 minutes, followed by a total of 28 to 34 cycles; denaturation at 93°C for 45 seconds, annealing at 62°C for 45 seconds, and extension at 72°C for 30 seconds).” In the legend for Figure 5, the symbol § denotes P < 0.05 in comparison with RA-SFBs; (§) denotes P < 0.10 in comparison with RA-SFBs. In the legend for Figure 6, the symbol + denotes P < 0.05 in comparison with the respective stimulus without inhibitor. Additionally in this article, Table 1 appeared incorrectly. The correct table appears here (see Table 1 ▶ ).
Table 1.
Clinical Characteristics of the Patients at the Time of Synovectomy/Sampling
| Patients (total) | Gender (m/f) | Age (yrs) | Disease duration (yrs) | RF (+/−) | ESR (mm/1h) | CRP* (mg/l) | # of ARA-criteria (RA) | Concomitant medication | (n) |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis (RA) | |||||||||
| 26 | 9/17 | 63.2 ± 2.0 | 14.6 ± 2.5 | 24/2 | 45.0 ± 5.3 | 25.9 ± 4.0 | 4.9 ± 0.2 | MTX | (12) |
| (n.d.=5) | Prednis. | (18) | |||||||
| Sulfas. | (4) | ||||||||
| Chloroquin | (1) | ||||||||
| Leflunomide | (3) | ||||||||
| NSAIDs | (21) | ||||||||
| Osteoarthritis | |||||||||
| 25 | 4/21 | 68.4 ± 1.8 | 4.7 ± 0.5 | 2/19 | 18.6 ± 3.9 | 4.6 ± 1.1 | 0.3 ± 0.1 | Prednis. | (2) |
| (n.d.=4) | (n.d.=2) | (n.d.=1) | MTX | (1) | |||||
| NSAIDs | (14) | ||||||||
| none | (10) | ||||||||
| Other arthritides | |||||||||
| EB32/ReA | m | 43 | 8 | + | 60 | 8.5 | 1 | none | |
| EB36/ReA | f | 31 | 0.13 | − | 50 | 63.8 | 0 | NSAIDs, Doxycyclin | |
| Joint trauma | |||||||||
| 7 | 3/4 | 31.9 ± 7.6 | 0.6 ± 0.4 | n.d. | n.d. | n.d. | 0.0 ± 0.0 | L-Thyroxin | (1) |
| Nifedipin | (1) | ||||||||
| Propanolol | (1) | ||||||||
| none | (5) | ||||||||
| Normals | |||||||||
| 8 | 4/4 | 51.8 ± 6.9 | 0.0 ± 0.0 | n.d. | n.d. | n.d. | 0.0 ± 0.0 | none | (8) |
Abbreviations are defined as follows: m, male; f, female; yrs, years; RF, rheumatoid factor; +/−, positive/negative; ESR, erythrocyte sedimentation rate (mm); CRP, C-reactive protein;
*, normal range: < 5 mg/l; ARA, American Rheumatism Association (now American College of Rheumatology); n.d., not determined; RA, rheumatoid arthritis; ReA, reactive arthritis; MTX, Methotrexate; Prednis., Prednisolone; Sulfas., Sulfasalazine; NSAIDs, non-steroidal anti-inflammatory drugs.
For the parameters age, disease duration, ESR, CRP, and # of ARA-Criteria (RA) means ± SEM are given; for the remaining parameters n numbers are provided.